SG11201705378RA - Methods of treating retinal diseases - Google Patents
Methods of treating retinal diseasesInfo
- Publication number
- SG11201705378RA SG11201705378RA SG11201705378RA SG11201705378RA SG11201705378RA SG 11201705378R A SG11201705378R A SG 11201705378RA SG 11201705378R A SG11201705378R A SG 11201705378RA SG 11201705378R A SG11201705378R A SG 11201705378RA SG 11201705378R A SG11201705378R A SG 11201705378RA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- retinal diseases
- treating retinal
- treating
- diseases
- Prior art date
Links
- 208000017442 Retinal disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/00727—Apparatus for retinal reattachment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462097753P | 2014-12-30 | 2014-12-30 | |
US201562116980P | 2015-02-17 | 2015-02-17 | |
US201562116972P | 2015-02-17 | 2015-02-17 | |
PCT/IL2015/050456 WO2016108219A1 (en) | 2014-12-30 | 2015-04-30 | Methods of treating retinal diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201705378RA true SG11201705378RA (en) | 2017-08-30 |
Family
ID=56284392
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201705378RA SG11201705378RA (en) | 2014-12-30 | 2015-04-30 | Methods of treating retinal diseases |
Country Status (18)
Country | Link |
---|---|
US (2) | US20180008458A1 (en) |
EP (1) | EP3240612B1 (en) |
JP (4) | JP2018501281A (en) |
KR (2) | KR102359257B1 (en) |
CN (3) | CN114533761A (en) |
AU (3) | AU2015373111B2 (en) |
BR (1) | BR112017014332A2 (en) |
CA (2) | CA2972700A1 (en) |
DK (1) | DK3240612T3 (en) |
EA (1) | EA201791518A1 (en) |
ES (1) | ES2843626T3 (en) |
HK (1) | HK1246179A1 (en) |
IL (1) | IL253244B2 (en) |
MX (1) | MX2017008818A (en) |
PH (1) | PH12017501217A1 (en) |
SG (1) | SG11201705378RA (en) |
WO (1) | WO2016108219A1 (en) |
ZA (1) | ZA201704359B (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL301479A (en) | 2009-11-17 | 2023-05-01 | Astellas Inst For Regenerative Medicine | Methods of producing human rpe cells and pharmaceutical preparations of human rpe cells |
JP2018502575A (en) | 2014-12-30 | 2018-02-01 | セル キュア ニューロサイエンシズ リミテッド | Evaluation method of retinal pigment epithelial cell population |
IL305070A (en) | 2014-12-30 | 2023-10-01 | Cell Cure Neurosciences Ltd | Rpe cell populations and methods of generating same |
BR112017014332A2 (en) | 2014-12-30 | 2018-01-02 | Cell Cure Neurosciences Ltd | retinal disease treatment methods |
EP3862425A1 (en) | 2015-07-29 | 2021-08-11 | Hadasit Medical Research Services and Development Ltd. | Large scale production of retinal pigment epithelial cells |
CA2993910A1 (en) | 2015-08-05 | 2017-02-09 | Cell Cure Neurosciences Ltd. | Preparation of photoreceptors for the treatment of retinal diseases |
IL269363B2 (en) * | 2017-03-16 | 2024-02-01 | Lineage Cell Therapeutics Inc | Methods for measuring therapeutic effects of retinal disease therapies |
WO2019028088A1 (en) | 2017-07-31 | 2019-02-07 | Biotime, Inc. | Compositions and methods for restoring or preventing loss of vision caused by disease or traumatic injury |
JP2021509110A (en) * | 2017-12-29 | 2021-03-18 | セル キュア ニューロサイエンシズ リミテッド | Retinal pigment epithelial cell composition |
CN108795864B (en) * | 2018-05-24 | 2021-08-24 | 中山大学中山眼科中心 | Method for obtaining retinal-like tissue rich in cones and rods by using human induced pluripotent stem cells |
US10264436B1 (en) * | 2018-05-29 | 2019-04-16 | Link Labs, Inc. | BLE networking systems and methods providing central and peripheral role reversal with independent peripheral network connectivity |
US20220033826A1 (en) * | 2018-08-31 | 2022-02-03 | University Of Florida Research Foundation, Incorporated | Adeno-associated viral vectors for the treatment of best disease |
WO2020229628A1 (en) * | 2019-05-15 | 2020-11-19 | Novo Nordisk A/S | Methods for obtaining eye field progenitor cells from human pluripotent stem cells |
EP3964227A1 (en) * | 2020-09-08 | 2022-03-09 | Curebiotec GmbH | Method for the treatment of a disease using pigment epithelium-derived factor (pedf) |
AU2021335639A1 (en) * | 2020-09-03 | 2023-03-09 | Curebiotec Gmbh | Pigment epithelium-derived factor (PEDF) for use in treatment of macular degeneration or choroidal neovascularisation |
KR102633321B1 (en) * | 2021-05-11 | 2024-02-05 | 연세대학교 산학협력단 | Pharmarceutical composition for preventing or treating of age-related macular degeneration |
CN115212233A (en) * | 2022-08-26 | 2022-10-21 | 北京市眼科研究所 | Composition and kit for treating retina-related diseases and application of composition and kit |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154600B (en) | 1971-02-10 | 1977-09-15 | Organon Nv | METHOD FOR THE DETERMINATION AND DETERMINATION OF SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES. |
NL154598B (en) | 1970-11-10 | 1977-09-15 | Organon Nv | PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING. |
NL154599B (en) | 1970-12-28 | 1977-09-15 | Organon Nv | PROCEDURE FOR DETERMINING AND DETERMINING SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES, AND TEST PACKAGING. |
US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
NL171930C (en) | 1972-05-11 | 1983-06-01 | Akzo Nv | METHOD FOR DETERMINING AND DETERMINING BITES AND TEST PACKAGING. |
US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
JP5395058B2 (en) | 2007-04-18 | 2014-01-22 | ハダシット メディカル リサーチ サーヴィシーズ アンド ディヴェロップメント リミテッド | Retinal pigment epithelial cells derived from stem cells |
ES2764473T3 (en) * | 2007-10-12 | 2020-06-03 | Astellas Inst For Regenerative Medicine | Improved methods for producing RPE cells and RPE cell compositions |
KR101025880B1 (en) * | 2008-10-23 | 2011-03-30 | 공희숙 | Method for the differentiation of human adult stem cells into insulin-secreting cells |
IL301479A (en) * | 2009-11-17 | 2023-05-01 | Astellas Inst For Regenerative Medicine | Methods of producing human rpe cells and pharmaceutical preparations of human rpe cells |
AU2012340020A1 (en) * | 2011-11-14 | 2014-07-03 | Astellas Institute For Regenerative Medicine | Pharmaceutical preparations of human RPE cells and uses thereof |
US9850463B2 (en) * | 2012-02-01 | 2017-12-26 | The Regents Of The University Of California | Methods of culturing retinal pigmented epithelium cells, including xeno-free production, RPE enrichment, and cryopreservation |
KR101483988B1 (en) * | 2012-04-09 | 2015-01-28 | 연세대학교 산학협력단 | Hollow Microneedle for Subretinal Injection and Extraction and Devices for Subretinal Injection and Extraction |
EP2951290B1 (en) | 2013-02-01 | 2017-11-29 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Method for generating retinal pigment epithelium (rpe) cells from induced pluripotent stem cells (ipscs) |
AU2014363032A1 (en) * | 2013-12-11 | 2016-06-09 | Pfizer Limited | Method for producing retinal pigment epithelial cells |
BR112017014332A2 (en) * | 2014-12-30 | 2018-01-02 | Cell Cure Neurosciences Ltd | retinal disease treatment methods |
IL305070A (en) | 2014-12-30 | 2023-10-01 | Cell Cure Neurosciences Ltd | Rpe cell populations and methods of generating same |
JP2018502575A (en) | 2014-12-30 | 2018-02-01 | セル キュア ニューロサイエンシズ リミテッド | Evaluation method of retinal pigment epithelial cell population |
KR101982801B1 (en) * | 2015-10-28 | 2019-05-30 | 서울대학교 산학협력단 | Composition for inducing differentiation to retinal pigment epithelium |
-
2015
- 2015-04-30 BR BR112017014332A patent/BR112017014332A2/en not_active Application Discontinuation
- 2015-04-30 ES ES15875361T patent/ES2843626T3/en active Active
- 2015-04-30 CN CN202210141757.7A patent/CN114533761A/en active Pending
- 2015-04-30 KR KR1020177021263A patent/KR102359257B1/en active IP Right Grant
- 2015-04-30 KR KR1020227003550A patent/KR102514912B1/en active IP Right Grant
- 2015-04-30 WO PCT/IL2015/050456 patent/WO2016108219A1/en active Application Filing
- 2015-04-30 CN CN202210144880.4A patent/CN114469998A/en active Pending
- 2015-04-30 MX MX2017008818A patent/MX2017008818A/en unknown
- 2015-04-30 SG SG11201705378RA patent/SG11201705378RA/en unknown
- 2015-04-30 DK DK15875361.6T patent/DK3240612T3/en active
- 2015-04-30 IL IL253244A patent/IL253244B2/en unknown
- 2015-04-30 CA CA2972700A patent/CA2972700A1/en not_active Abandoned
- 2015-04-30 JP JP2017535831A patent/JP2018501281A/en active Pending
- 2015-04-30 CN CN201580076318.0A patent/CN107427534A/en active Pending
- 2015-04-30 EP EP15875361.6A patent/EP3240612B1/en not_active Revoked
- 2015-04-30 CA CA3175175A patent/CA3175175A1/en active Pending
- 2015-04-30 AU AU2015373111A patent/AU2015373111B2/en active Active
- 2015-04-30 EA EA201791518A patent/EA201791518A1/en unknown
- 2015-04-30 US US15/539,565 patent/US20180008458A1/en not_active Abandoned
-
2017
- 2017-06-27 ZA ZA2017/04359A patent/ZA201704359B/en unknown
- 2017-06-29 PH PH12017501217A patent/PH12017501217A1/en unknown
-
2018
- 2018-05-03 HK HK18105715.3A patent/HK1246179A1/en unknown
-
2020
- 2020-05-27 JP JP2020092030A patent/JP2020143137A/en active Pending
-
2021
- 2021-09-08 AU AU2021229196A patent/AU2021229196A1/en not_active Abandoned
-
2022
- 2022-07-04 JP JP2022107516A patent/JP2022125160A/en active Pending
- 2022-09-13 US US17/943,462 patent/US20230028133A1/en active Pending
-
2023
- 2023-10-27 AU AU2023255009A patent/AU2023255009A1/en not_active Abandoned
- 2023-12-11 JP JP2023208119A patent/JP2024023611A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL283561B (en) | Methods for treating ocular diseases | |
HK1246179A1 (en) | Methods of treating retinal diseases | |
HK1231417A1 (en) | Compounds for treating ophthalmic diseases and disorders | |
GB201701673D0 (en) | Methods of well treatment | |
PT3212233T (en) | Combination therapy for treatment of disease | |
IL246791A0 (en) | Compositions and methods for treating ocular diseases | |
FI3851537T3 (en) | Treatment of hyperbilirubinemia | |
ZA201807084B (en) | Methods of treatment of cholestatic diseases | |
HK1245127A1 (en) | Methods and compositions for treating brain diseases | |
HK1258994A1 (en) | Methods for treatment of diseases | |
HK1247818A1 (en) | Method of treating diseases | |
GB201410116D0 (en) | Method of treatment | |
IL251769A0 (en) | Methods of treating ocular conditions | |
GB201416832D0 (en) | Methods of treatment | |
GB201412578D0 (en) | Treatment of neurological diseases | |
HK1243937A1 (en) | Methods of treating diseases | |
IL259381B (en) | Mirabegron for the treatment of retinal diseases | |
PL3302463T3 (en) | Use of 3-deoxyanthocyanidins for treating ocular diseases | |
GB201512139D0 (en) | Methods of treatment | |
PT3851537T (en) | Treatment of hyperbilirubinemia | |
GB201414023D0 (en) | Treatment of autoimmune diseases | |
GB201421982D0 (en) | Method of treatment | |
GB201421980D0 (en) | Method of treatment | |
GB201415331D0 (en) | Method of treatment | |
GB201414780D0 (en) | Method Of Treatment |